Note 4 - Collaboration and License Agreement (Details Textual) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended		23 Months Ended
	Nov. 06, 2020	Oct. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer, Excluding Assessed Tax, Total			$ 4,956	$ 2,412	$ 7,663	$ 6,457
Contract with Customer, Liability, Current			5,432		5,432		$ 5,432	$ 4,571
Contract with Customer, Liability, Current			1,024		1,024		1,024	3,548
3D Medicines, Inc [Member]
Collaborative Agreement, Maximum Clinical Development, Regulatory and Commercial Milestone Payments	$ 207,000
Proceeds from Collaborators					15,000		27,000
Collaborative Agreement, Royalty, Period After First Commercial Sale of Product (Year)	10 years
Revenue, Remaining Performance Obligation, Amount			27,000		27,000		27,000
Revenue from Contract with Customer, Excluding Assessed Tax, Total					3,100
Contract with Customer, Liability, Total			6,400		6,400		6,400	$ 8,100
Contract with Customer, Liability, Current			5,400		5,400		5,400
Contract with Customer, Liability, Current			1,000		$ 1,000		1,000
Service Period (Year)					1 year 6 months
3D Medicines, Inc [Member] | Research and Development Services [Member]
Revenue, Remaining Performance Obligation, Amount			14,500		$ 14,500		14,500
Revenue from Contract with Customer, Excluding Assessed Tax, Total					4,900	$ 2,300
3D Medicines, Inc [Member] | License [Member]
Revenue, Remaining Performance Obligation, Amount			12,500		$ 12,500		$ 12,500
Revenue from Contract with Customer, Excluding Assessed Tax, Total			$ 2,800	$ 4,200
3D Medicines, Inc [Member] | Subsequent Event [Member]
Proceeds from Collaborators		$ 6,000